Table 1 Best‐corrected visual acuity and foveal thickness in patients treated with topical 2% dorzolamide.
Patient no | Visit number, months of follow‐up | Vision | FT, mean FT difference (%) | FZT,* mean FZT difference (%) | |||
---|---|---|---|---|---|---|---|
OD | OS | OD | OS | OD | OS | ||
1 | 1 | 20/50 (−2) | 20/30 (−2) | 356 | 491 | 343 | 456 |
2, 1 | 20/40 (+2) | 20/25 (−1) | 158 (−56) | 419 (−15) | 219 (−36) | 395 (−13) | |
3, 2 | 20/25 (−2) | 20/25 (−1) | 144 (−60) | 464 (−5) | 208 (−39) | 428 (−6) | |
4, 4 | 20/30 (+2) | 20/25 (−2) | 158 (−56) | 482 (−2) | 225 (−34) | 435 (−5) | |
5, 10 | 20/30 (−1) | 20/25 (−1) | 255 (−28) | 423 (−14) | 284 (−17) | 404 (−11) | |
2 | 1 | 20/40 (+2) | 20/40 (−3) | 515 | 496 | 514 | 495 |
2, 2 | 20/40 (−1) | 20/40 (−3) | 396 (−23) | 482 (−3) | 412 (−20) | 458 (−7) | |
3, 3 | 20/40 (−2) | 20/40 (−2) | 404 (−22) | 441 (−11) | 413 (−20) | 445 (−10) | |
4, 5 | 20/40 | 20/40 (−2) | 378 (−27) | 395 (−20) | 386 (−25) | 402 (−19) | |
5, 7 | 20/30 (−2) | 20/40 (−2) | 423 (−18) | 444 (−10) | 425 (−17) | 440 (−11) | |
6, 9 | 20/30 | 20/40 (−1) | 364 (−29) | 372 (−25) | 375 (−27) | 376 (−24) | |
7, 12 | 20/40 (+2) | 20/40 (+2) | 461 (−10) | 502 (+1) | 463 (−10) | 493 (−1) | |
3 | 1 | 20/40 (−2) | 20/50 (+1) | 574 | 523 | 530 | 489 |
2, 2 | 20/30 | 20/30 (+1) | 174 (−70) | 201 (−62) | 235 (−56) | 254 (−48) | |
3, 3 | 20/30 | 20/30 (+2) | 179 (−69) | 177 (−66) | 239 (−55) | 230 (−53) | |
4, 4 | 20/30 | 20/30 (+1) | 200 (−65) | 198 (−62) | 269 (−49) | 245 (−50) | |
5, 10 | 20/30 (+2) | 20/30 (+2) | 163 (−72) | 179 (−66) | 227 (−57) | 230 (−53) | |
6, 15 | 20/30 | 20/30 (+2) | 234 (−59) | 221 (−58) | 288 (−46) | 260 (−47) | |
4 | 1 | 20/50 (−3) | 20/60 (−1) | 315 | 338 | 321 | 333 |
2, 1 | 20/40 (−1) | 20/60 (+1) | 250 (−21) | 280 (−17) | 264 (−18) | 284 (−15) | |
3, 3 | 20/40 (−2) | 20/60 | 226 (−28) | 238 (−30) | 242 (−25) | 251 (−25) | |
4, 8 | 20/40 | 20/60 | 213 (−32) | 242 (−28) | 239 (−25) | 261 (−22) | |
5, 13 | 20/40 (+2) | 20/50 (−1) | 213 (−32) | 281 (−17) | 243 (−24) | 295 (−11) | |
5 | 1 | 20/30 (+1) | 20/40 (+2) | 340 | 311 | 349 | 323 |
2,1 | 20/25 | 20/30 (+2) | 263 (−23) | 249 (−20) | 288 (−17) | 280 (−13) | |
3, 2 | 20/25 | 20/25 (−2) | 309 (−9) | 285 (−8) | 318 (−9) | 302 (−6) | |
4, 3 | 20/25 (+1) | 20/25 (+1) | 298 (−12) | 250 (−20) | 309 (−11) | 279 (−14) | |
5, 4 | 20/25 (−3) | 20/30 (+2) | 220 (−35) | 219 (−30) | 261 (−25) | 250 (−23) | |
6, 9 | 20/25 (−3) | 20/30 (−1) | 222 (−35) | 250 (−20) | 267 (−23) | 278 (−14) | |
7, 12 | 20/25 (−2) | 20/30 (−1) | 213 (−37) | 233 (−25) | 258 (−26) | 263 (−19) | |
6 | 1 | 20/20 (−2) | 20/25 (−2) | 273 | 643 | 303 | 607 |
2, 2 | 20/20 | 20/25 (−1) | 239 (−12) | 523 (−19) | 273 (−10) | 516 (−15) | |
3, 3 | 20/20 | 20/25 (−2) | 228 (−16) | 413 (−36) | 262 (−14) | 427 (−30) | |
4, 5 | 20/20 | 20/20 (−1) | 237 (−13) | 512 (−20) | 272 (−10) | 506 (−17) | |
5, 7 | 20/20 | 20/20 (−3) | 241 (−12) | 584 (−9) | 280 (−8) | 567 (−7) | |
7 | 1 | 20/30 (−3) | 20/30 (−1) | 310 | 225 | 307 | 256 |
2, 1 | 20/30 (+2) | 20/25 (+2) | 228 (−26) | 162 (−28) | 251 (−18) | 217 (−15) | |
3, 3 | 20/25 (−2) | 20/25 (−2) | 169 (−45) | 150 (−33) | 215 (−30) | 207 (−19) | |
4, 5 | 20/25 (−1) | 20/25 (−2) | 217 (−30) | 271 (+20) | 159 (−48) | 223 (−13) | |
5, 7 | 20/25 (−1) | 20/25 (−2) | 160 (−48) | 155 (−31) | 208 (−32) | 214 (−16) | |
6, 10 | 20/25 (−2) | 20/25 (−1) | 166 (−46) | 145 (−36) | 224 (−27) | 219 (−14) | |
7, 13 | 20/25 (−2) | 20/25 (−2) | 234 (−25) | 155 (−31) | 266 (−13) | 216 (−16) | |
8 | 1 | 20/60 (+2) | 20/30 (+1) | 261 | 326 | 256 | 334 |
2, 1 | 20/50 (−3) | 20/30 (+2) | 217 (−17) | 230 (−34) | 224 (−13) | 253 (−24) | |
3, 3 | 20/50 (−2) | 20/25 (−2) | NA | 208 (−36) | NA | 246 (−26) | |
4, 6 | 20/60 (−2) | 20/25 (−2) | 214 (−18) | 208 (−36) | 237 (+7) | 235 (−30) | |
5, 9 | 20/70 (+1) | 20/30 (−1) | 259 (−1) | 286 (−12) | 260 (+1) | 307 (−8) | |
6, 11 | 20/50 (−2) | 20/25 (−2) | 235 (−10) | 260 (−26) | 270 (+5) | 281 (−16) |
FT, foveal thickness; FZT, foveal zone thickness; OD, oculus dexter; OS, oculus sinister.
*FZT (defined as the central 1000 µ centred on the fovea).
†Bold numbers represent a significant difference of FT and FZT between visits for each patient. Determination of significant difference was based on intervisit variation (upper range and mean (2SD)) of FT and FZT changes in a control group (n = 5) with retinitis pigmentosa patients with continuing medical education (CME) (FT>16%, FZT>11%).
Positive and negative values for differences represent a direction of change: a “+” value indicates an increase in the FT or FZT, whereas a “−” value indicates a decrease in the FT or FZT. NA indicates that data could not be obtained.